by Staff Reporter | Mar 20, 2026 | News
By Staff Reporter |
Congressman Abe Hamadeh (R-AZ-08) successfully convinced the FDA to reverse its decision to remove desiccated thyroid medications from the market.
The congressman issued a press release last week detailing this latest development in the ongoing battle between patient autonomy and federal oversight. Hamadeh explained that the FDA won’t take action to pull DTE medications from the market while companies work toward formal FDA approval.
The usage of DTE in medications predated the creation of the FDA; they were grandfathered in due to their safety and efficacy. Conservative government estimates placed DTE users at 1.5 million in 2024.
Hamadeh clarified that DTE patients will be able to continue getting their prescriptions without interruption, but that the FDA course reversal doesn’t constitute a permanent approval. The FDA noted in an update last week that it changed course to a “risk-based enforcement approach” rather than a blanket removal, and pledged to issue formal draft guidance on compliance priorities by this August.
“As I have said before, it was clear to me based on the feedback that I have received from countless constituents that the FDA’s action against these medications was likely not science-based,” stated Hamadeh. “So, I did not hesitate to question the FDA’s action that many of my constituents believe would negatively impact their quality of life.”
Certain hypothyroid patients rely on these natural thyroid medications, or desiccated thyroid extract (DTE), due to inefficacy or adverse reactions to the synthetic, FDA-approved alternative. DTE medications are made from dried, ground animal thyroid glands (usually porcine).
Most medical practitioners default to the prescription of the synthetic thyroid drug levothyroxine, approved by the FDA in 2000. These and several other synthetic thyroid drugs approved by the FDA provide only one of the two main hormones produced by the thyroid gland, T3 and T4. Unlike their synthetic counterparts, DTE medications provide both T3 and T4.
Last August, the FDA announced it would make DTE medications unavailable within a year at the direction of Center for Drug Evaluation and Research (CDER) Director George Tidmarsh. Tidmarsh had assumed leadership of CDER just one month before the enforcement action — his very first on the job.
Three months later, in November, Tidmarsh resigned following allegations in a lawsuit that he used his CDER power to harm a former associate, Kevin Tang, by taking enforcement actions against certain drugs — including several DTE medications.
According to the lawsuit, Tidmarsh was accused of attempting to extort American Laboratories, in which Tang was board chair, shortly after the FDA announced its enforcement action.
American Laboratories manufactures Armour Thyroid and NP Thyroid, two of the top brand names for DTE medications. The two drugs constitute their core product line.
Over a month later, Tidmarsh turned his attention to a different drug manufactured by another company chaired by Kevin Tang, Aurinia Pharmaceuticals. In a since-deleted LinkedIn post, Tidmarsh made various accusations against the company’s nephritis drug, voclosporin, which the company alleged were false and defamatory.
LinkedIn appears to be a means by which Tidmarsh would put his former associates on notice. In the months leading up to his appointment as CDER director last July, Tidmarsh warned in another LinkedIn post that his first course of action would be to ban DTE medications.
“The new FDA needs to remove harmful, useless drugs from the market. Let’s start with desiccated thyroid extract,” said Tidmarsh. “An unapproved, crude pig tissue extract that is proven worse than synthetic thyroid hormone and harmful. Working with the new FDA to remove it permanently from the market.”
Following public reporting on Tidmarsh’s resignation and the accusations against him, Hamadeh urged FDA Commissioner Makary to withdraw or indefinitely suspend enforcement actions against DTE medications.
Despite Tidmarsh’s exit, the FDA maintains its claim that its concerns with DTE medications originate not with the personal vendettas of its former director, but with patient complaints and reports of adverse events. The FDA didn’t provide further detail on these alleged complaints or reports.
The FDA Adverse Event Reporting System (FAERS) reflected DTE medications having over 3,000 cases from 1970 to 2026. Less than 400 complaints were of the drugs being ineffective and less than 60 reports were of death as a reaction. AZ Free News included all available top name-brand and generic naming of DTE medications in our search: Armour Thyroid, NP Thyroid, Thyroid, Nature-Throid, and porcine thyroid.
Conversely, levothyroxine and its name-brand counterpart, Synthroid, alone accumulated over 46,000 cases of suspected adverse events since 2000, of which nearly 4,000 complaints were of the drugs being ineffective. The synthetic drugs have over 1,000 reports of death as a reaction.
AZ Free News is your #1 source for Arizona news and politics. You can send us news tips using this link.
by Ethan Faverino | Nov 10, 2025 | News
By Ethan Faverino |
Congressman Abe Hamadeh urged the Food and Drug Administration (FDA) Commissioner, Dr. Martin Makary, to immediately withdraw or indefinitely suspend enforcement actions against desiccated thyroid medications.
This follows explosive allegations of misconduct by former Center for Drug Evaluation and Research (CDER) Director George Tidmarsh.
Dr. Tidmarsh resigned on November 2, 2025, amid a Department of Health and Human Services (HHS) investigation into claims that he abused his regulatory authority to target desiccated thyroid drugs—medications safely used by 1.5 million Americans for decades—in an effort to harm business rival, Kevin Tang.
Aurinia Pharmaceuticals filed a lawsuit the same day, alleging Tidmarsh used official FDA resources to “target multiple companies” linked with Tang, including a company where Tang serves as board chairman, American Laboratories, a key supplier of active ingredients for desiccated thyroid drugs.
The timeline raises serious concerns as Tidmarsh assumed leadership of CDER in July 2025, just one month before the FDA issued enforcement warnings against these very medications.
Reports indicate Tidmarsh was placed on administrative leave on November 1st, before resigning the following day.
In Congressman Hamadeh’s first letter, he raised alarms about the FDA’s actions, warning that restrictions could disrupt care for thousands of veterans and seniors in Arizona’s 8th District who rely on these treatments. Although Hamadeh’s office followed up many times, the FDA provided a very generic response to their inquiries.
Now, in a November 4th letter to Commissioner Makary, Congressman Hamadeh demanded immediate action, including:
- Suspension of all enforcement actions against desiccated thyroid drugs initiated on or after July 2025.
- A transparent public and congressional accounting of all regulatory decisions involving thyroid medications, including communications, conflicts of interest, and internal concerns about Dr. Tidmarsh.
- 180-day advance notice to Congress before any future enforcement, with scientific justification and patient impact assessments.
- Guaranteed uninterrupted access for the 1.5 million patients dependent on these medications.
- Substantive responses to his original August inquiries.
“It was clear to me, based on the feedback that I have received from countless constituents, that the FDA’s action against these medications was likely not science-based,” said Congressman Hamadeh. “Given our government’s reaction to COVID-19, it is not hard to imagine that bad actors in our government have personal agendas and no regard for science or our citizens.”
“The FDA’s primary mission should be ensuring drug safety and efficacy, not unnecessarily restricting access to medications with established track records of safety and effectiveness,” concluded Congressman Hamadeh. “The American people expect that FDA regulatory actions be grounded in science and patient safety, not personal scores or abuse of authority.”
Ethan Faverino is a reporter for AZ Free News. You can send him news tips using this link.
by Ethan Faverino | Aug 22, 2025 | News
By Ethan Faverino |
On August 6, 2025, the Food and Drug Administration (FDA) sent letters to manufacturers, importers, and distributors of unapproved animal-derived thyroid medications, notifying them of the agency’s intent to take enforcement action due to concerns over safety, potency, and dosing consistency.
These medications, derived from dried animals’ thyroid glands, are used by an estimated 1.5 million patients in the U.S. but are not FDA-approved, unlike synthetic alternatives like levothyroxine, which serve approximately 22 million patients.
The agency has allowed a 12-month transition period for patients to switch to FDA-approved medications.
Earlier this week, Congressman Abe Hamadeh (AZ-08) issued a formal inquiry to Dr. Martin Makary, Commissioner of the FDA, seeking clarity on recent agency actions that could restrict access to desiccated thyroid medications such as Armour Thyroid, NP Thyroid, Nature-Thyroid, and Natural Thyroid, which are critical for many patients managing hypothyroidism.
In his letter to Dr. Makary, Congressman Hamadeh emphasized the concerns of his constituents, particularly the veterans and seniors in Arizona’s 8th Congressional District, who rely on desiccated thyroid medications for effective treatment.
“Many of these patients have found desiccated thyroid medications to be more effective than synthetic alternatives for managing their thyroid conditions,” said Hamadeh. “Any disruption to their treatment regimens could have serious health consequences and undermine the doctor-patient relationship.”
Congressman Hamadeh requested that the FDA provide answers by September 5, 2025, to the following questions:
- What specific actions, if any, is the FDA taking regarding desiccated thyroid medications like Armour Thyroid?
- What evidence supports any potential restrictions on these long-established medications that have been safely used for decades?
- Has the FDA conducted a comprehensive analysis of how any restrictions would affect patients who rely on these medications?
- If restrictions are being considered, what steps will the FDA take to ensure patients maintain access to effective thyroid treatment options?
Congressman Hamadeh continued to state, “This issue reflects broader concerns about federal agency overreach into medical decisions that should remain between patients and their physicians. The FDA’s primary mission should be ensuring drug safety and efficacy, not unnecessarily restricting access to medications with established track records of safety and effectiveness.”
Dr. Makary has already responded to the backlash and public concerns via X (Twitter), stating that the “FDA is committed to pursuing the first-ever approval of desiccated thyroid extract, pending results of the ongoing clinical trials. In the meantime, we will ensure access for all Americans.”
Ethan Faverino is a reporter for AZ Free News. You can send him news tips using this link.
by Matthew Holloway | Apr 3, 2025 | News
By Matthew Holloway |
Arizona Senate Majority Leader Janae Shamp, who has spearheaded a raft of medically-related legislation, hailed the confirmation of the new U.S. Food and Drug Administration (FDA) Commissioner Dr. Marty Makary.
Along with expressing her approval of Makary, Shamp emphasized her commitment to her “Make Arizona Healthy Again” Agenda, complementing the national policy of “Make America Healthy Again” undertaken by the Trump administration.
In a press release, the Arizona Senate GOP explained that as a perioperative nurse, Shamp “witnessed firsthand instances of corruption within the healthcare system, big companies using influence to impact state agency operations, as well as negligent government actions and overreach leading to negative health consequences for Arizonans.”
Shamp said in a statement:
“It’s time to clean up public health in our country, and Dr. Makary is the right man for the job. I am so excited to see him as our new FDA Commissioner. As an experienced surgeon, Dr. Makary has a lifetime of exceptional service in the field of health and wellness. He will undoubtedly help President Donald J. Trump and Secretary Robert F. Kennedy, Jr. carry out their goals to make America healthy again.”
She continued, “Our food supply is full of toxins and carcinogens. Americans are incredibly overmedicated. I look forward to seeing his great work at the FDA to address these critical issues, and I am proud to support the MAHA movement with state legislation that is in lockstep with the goals of the Trump Administration to create a healthier society.”
As previously reported by AZ Free News, Shamp’s bill, SB 1586, is designed to create legal protections for children and teens who have been subjected to so-called ‘gender transition procedures,’ setting the ground work for potential medical malpractice litigation. Shamp also co-sponsored HB 2164, introduced by her Rep. Leo Biasiucci, to “ban ultra-processed foods containing harmful additives from being served in public school meals.”
In addition, Shamp has also introduced or co-sponsored several healthcare reform measures including: SB 1102, to prevent insurance companies from acting as the “middleman” from “unwarranted interference in the doctor-patient relationship,” which was signed into law last week; SB 1235, protecting the State of Arizona from potential anti-trust lawsuits by restructuring health regulatory boards; and HB 2165, which would prohibit Supplemental Nutrition Assistance Program (SNAP) enrollees from purchasing soda with taxpayer funded SNAP benefits.
Matthew Holloway is a senior reporter for AZ Free News. Follow him on X for his latest stories, or email tips to Matthew@azfreenews.com.
by Corinne Murdock | Aug 19, 2023 | News
By Corinne Murdock |
The Scottsdale-based Alliance Defending Freedom (ADF) secured a federal court ruling that effectively halts mail-order abortions.
On Wednesday, the Fifth Circuit Court of Appeals ruled that the Food and Drug Administration (FDA) must reinstate its safety restrictions for mifepristone use. In effect, the ruling limits mifepristone’s use to the first seven weeks of pregnancy, as well as requires an in-person visit with a provider prior to prescription.
This is the Texas court’s second ruling against mifepristone access. In April, the court issued an injunction against the abortion drug. The same hour of that injunction, a Washington federal court ruled that the FDA must continue providing mifepristone. Several weeks after those conflicting orders, the Supreme Court halted the Texas court’s injunction until all litigation had concluded.
ADF sued the FDA last November on behalf of four pro-life medical groups, who argued that mifepristone shouldn’t have been approved by the FDA over 20 years ago and should be removed from the market.
The FDA approved mifepristone in 2000, during the Clinton administration, using a fast-tracked approval process. The FDA justified approval by reclassifying abortion as a “serious or life-threatening illness” and mifepristone as a “meaningful therapeutic benefit.” In a 2008 report, the Governmental Accountability Office (GAO) noted the medical community’s widespread criticism of the basis for mifepristone’s approval.
“Critics have argued that unwanted pregnancy should not be considered a serious or life-threatening illness,” stated the GAO report.
Mifepristone’s efficacy and safety are dubious. The drug’s usage has been linked to hundreds of cases of infections and death, if not more. Government studies have estimated adverse effects of the drug occurring in as many as one in five women. The FDA also failed to convince the New Orleans court of the drug’s safety.
“[I]n loosening mifepristone’s safety restrictions, [the] FDA failed to address several important concerns about whether the drug would be safe for the women who use it,” read the majority opinion.
Yet, state leaders have advocated for access to the abortion drug. Attorney General Kris Mayes’ office claims the drug is “incredibly safe” and that restrictions on it are “unnecessary.”
In June, Hobbs issued an executive order usurping county attorneys’ authority over prosecuting abortion law violations.
In March, Mayes encouraged pharmacies to give out abortion pills. In May, Mayes joined an amicus brief to advocate for the upholding of mifepristone’s FDA approval.
Hours after the circuit court ruling, Mayes’ new Reproductive Rights Unit issued guidance on how individuals can hide their data, such as internet history and communications, when seeking abortions. The new unit is headed by deputy solicitor general Hayleigh Crawford.
The attorney general didn’t issue a direct response to this week’s ruling, but the data privacy guidance and corresponding meeting appeared to be an indirect response of sorts.
Featured guests at the meeting included:
- Chris Love, board member and senior advisor for Planned Parenthood Advocates of Arizona, and attorney at Kewenvoyouma Law;
- Sheena Chiang, co-chair of the Planned Parenthood Arizona Board of Directors, and attorney for the Maricopa County Legal Defender’s office;
- Jodi Liggett, founder of the progressive think tank and advocacy group Arizona Center for Women’s Advancement, former deputy chief of staff for Phoenix Mayor Kate Gallego, former vice president of external affairs and executive director for Planned Parenthood of Arizona, former senior policy advisor for Phoenix Mayor Greg Stanton, former CEO of Arizona Foundation for Women, and former policy advisor for former Gov. Jane Hull;
- Bré Thomas, CEO of Affirm Sexual and Reproductive Health For All, former Arizona Department of Health Services manager and senior policy advisor, former Arizona Department of Economic Security executive assistant to the deputy director, and former women’s health policy advisor for former Gov. Janet Napolitano;
- Cadey Harrel, doctor and founder of Agave Community Health and Wellness;
- Tonya Irick, director of abortion clinic Family Planning Associates Medical Group
Corinne Murdock is a reporter for AZ Free News. Follow her latest on Twitter, or email tips to corinne@azfreenews.com.
